BridgeMD
New treatment option for Locally Advanced Nasopharyngeal Carcinoma
Official title Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
ClinicalTrials.gov ID: NCT05892354
What this study is testing
- What it's testing
- The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Age 18-70 years old, male or non-pregnant women;
- Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);
- Newly diagnosed stage III-IVa (8th AJCC/UICC stage) NPC patients;
- The levels of major organ function meet the following criteria: (1)Hematology: WBC ≥ 3.0 × 10\^9/L, ANC ≥ 1.5 × 10\^9/L, PLT ≥ 100 × 10\^9/L, HGB ≥...
You likely can't join if
- History of investigational Oral Impact®/ENSURE® use within the month prior to enrollment;
- Known allergy or intolerance to any component of investigational Oral Impact®/ENSURE® or related chemotherapy drugs;
- Poor glycemic control in patients with diabetes;
- Patients with autoimmune diseases;
- Patients with active infections;
- Patients who have received radiation therapy or other anti-tumor treatments in the past;
See the full eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Age 18-70 years old, male or non-pregnant women;
- Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);
- Newly diagnosed stage III-IVa (8th AJCC/UICC stage) NPC patients;
- The levels of major organ function meet the following criteria: (1)Hematology: WBC ≥ 3.0 × 10\^9/L, ANC ≥ 1.5 × 10\^9/L, PLT ≥ 100 × 10\^9/L, HGB ≥ 90 g/L; (2) Liver function: ALT, AST≤2.5 times the upper limit of...
- History of investigational Oral Impact®/ENSURE® use within the month prior to enrollment;
- Known allergy or intolerance to any component of investigational Oral Impact®/ENSURE® or related chemotherapy drugs;
- Poor glycemic control in patients with diabetes;
- Patients with autoimmune diseases;
- Patients with active infections;
- Patients who have received radiation therapy or other anti-tumor treatments in the past;
- Patients with a history of other malignant tumors;
- Presence of oral mucositis at baseline;
- Malnutrition at baseline;
- Patients who cannot eat the required amount of food at baseline and require parenteral or enteral nutrition;
- Inability to eat soft solid foods at baseline;
- History of human immunodeficiency virus (HIV) or active hepatitis B/C virus infection;
- Participation in other intervention clinical studies within one month;
- people deemed by the investigator to have other factors that may force them to terminate the study, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, significantly...
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
- Guangzhou, Guangdong, China
- Huizhou, Guangdong, China
- Guilin, Guangxi, China
- Liuzhou, Guangxi, China
- Nanning, Guangxi, China
- Wuzhou, Guangxi, China
- Yulin, Guangxi, China
- Haikou, Hainan, China
- Nanchang, Jiangxi, China
- Qingdao, Shandong, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China; Guangzhou, Guangdong, China; Huizhou, Guangdong, China; Guilin, Guangxi, China; Liuzhou, Guangxi, China; Nanning, Guangxi, China and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.